uniQure stock crashes as Huntington’s gene therapy data weaken
Shares of gene therapy developer uniQure crashed after the company released an updated data readout for its experimental Huntington's disease treatment, ifezuntirgene inilparvovec, also known as AMT-130. Although the therapy continued to show a dose-dependent slowing of disease progression through 48 months, it failed to hit statistical significance on a primary clinical measure. The missed statistical endpoint triggered a massive sell-off among investors and sent partner ClearPoint Neuro shares down 24 percent.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Shares of gene therapy developer uniQure N.V. cratered 64 percent Tuesday morning following an updated data readout for its experimental Huntington's disease treatment, ifezuntirgene inilparvovec (AMT-130).
- ✓ The treatment continued to show a dose-dependent slowing of disease progression, but failed to hit statistical significance on a primary clinical measure at 48 months.
- ✓ ClearPoint Neuro shares fell 24 percent following the uniQure AMT-130 trial update.
What changed
uniQure released 48-month data from an ongoing Phase I/II trial showing that the experimental Huntington's gene therapy missed statistical significance on its primary clinical measure.
Live updates
-
uniQure Stock Plunges as Huntington's Gene Therapy Data Disappoints
Shares of gene therapy developer uniQure crashed after the company released an updated data readout for its experimental Huntington's disease treatment, ifezuntirgene inilparvovec, also known as AMT-130. Although the therapy continued to show a dose-dependent slowing of disease progression through 48 months, it failed to hit statistical significance on a primary clinical measure. The missed statistical endpoint triggered a massive sell-off among investors and sent partner ClearPoint Neuro shares down 24 percent.
Why it matters
The experimental treatment is being evaluated in an ongoing Phase I/II trial to address Huntington's disease, a severe neurodegenerative condition. While long-term data showed ongoing physiological effects, the failure to clear the statistical threshold on primary clinical measures at 48 months severely dampened market expectations. Market reactions included dramatic valuation drops for uniQure alongside a significant fall in shares of ClearPoint Neuro.
What is confirmed
- Shares of gene therapy developer uniQure N.V. cratered 64 percent Tuesday morning following an updated data readout for its experimental Huntington's disease treatment, ifezuntirgene inilparvovec (AMT-130).
- The treatment continued to show a dose-dependent slowing of disease progression, but failed to hit statistical significance on a primary clinical measure at 48 months.
- ClearPoint Neuro shares fell 24 percent following the uniQure AMT-130 trial update.
What to watch next
- Further regulatory or corporate disclosures regarding the Phase I/II trial path for AMT-130
- Additional analyses of long-term patient data from the ongoing trial
confidence 100%Sources used for this update (10)
- Fierce Biotech — uniQure stock crashes as Huntington’s gene therapy data weaken
- STAT — UniQure’s gene therapy continues to slow Huntington’s progression after four years
- Reuters — UniQure plunges as Huntington's trial data disappoints investors
- Bloomberg.com — UniQure Sinks After Worse-Than-Expected Huntington’s Results
- Yahoo Finance — ClearPoint Neuro Shares Fall 24% Following uniQure AMT-130 Trial Update
- GlobeNewswire — uniQure Announces Additional Data from Ongoing Phase I/II
- finance.yahoo.com — uniQure plunges 65% as 48-month Huntington’s gene therapy ...
- blockonomi.com — uniQure (QURE) Stock Crashes 48% on Disappointing Huntington ...
- www.cafepharma.com — uniQure stock crashes as Huntington’s gene therapy data ...
- finance.yahoo.com — UniQure's Huntington's therapy fails to significantly slow ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community